Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
Frontiers in Neurology
|
October 11, 2021
CRMP5 Antibodies-Diagnostic Challenges
Cecilie Totland, Mette Haugen, Christian Vedeler
Journal of Neurology, Neurosurgery, and Psychiatry
|
April 19, 2013
Neurological manifestations related to level of voltage-gated potassium channel antibodies
Henning Olberg, Mette Haugen, Anette Storstein, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|
February 11, 2025
Magne Solberg Nes, Jogrim Søyland, Mette Haugen, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
February 3, 2021
Paraneoplastic Cerebellar Degeneration: The Importance of Including CDR2L as a Diagnostic Marker
Ida Herdlevær, Mette Haugen, Kibret Mazengia, et al.
Journal of Neuroimmunology
|
November 25, 2021
Expression of cerebellar degeneration-related proteins CDR2 and CDR2L in human and rat brain tissue
Margrethe Raspotnig, Torbjørn Kråkenes, Ida Herdlevær, et al.
Oncotarget
|
May 31, 2018
Expression of the onconeural protein CDR1 in cerebellum and ovarian cancer
Cecilie Totland, Torbjørn Kråkenes, Kibret Mazengia, et al.
Annals of Neurology
|
May 24, 2020
Reply to "CDR2 and CDR2L Yo Antigens in Paraneoplastic Cerebellar Degeneration"
Torbjørn Kråkenes, Ida Herdlevaer, Margrethe Raspotnig, et al.
Cancer Immunology, Immunotherapy : CII
|
August 15, 2009
Antibody to CCDC104 is associated with a paraneoplastic antibody to CDR2 (anti-Yo)
Cecilie Totland, Geir Bredholt, Mette Haugen, et al.
Acta Neuropathologica
|
October 25, 2014
Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis
Manja Schubert, Debabrata Panja, Mette Haugen, et al.
European Journal of Neurology
|
March 13, 2023
A cerebellar degeneration-related protein 2-like cell-based assay for anti-Yo detection in patients with paraneoplastic cerebellar degeneration
Kjell Inge Erikstad, Ida Herdlevaer, Elise Peter, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
Frontiers in Neurology
|
October 11, 2021
CRMP5 Antibodies-Diagnostic Challenges
Cecilie Totland, Mette Haugen, Christian Vedeler
Journal of Neurology, Neurosurgery, and Psychiatry
|
April 19, 2013
Neurological manifestations related to level of voltage-gated potassium channel antibodies
Henning Olberg, Mette Haugen, Anette Storstein, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|
February 11, 2025
Magne Solberg Nes, Jogrim Søyland, Mette Haugen, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
February 3, 2021
Paraneoplastic Cerebellar Degeneration: The Importance of Including CDR2L as a Diagnostic Marker
Ida Herdlevær, Mette Haugen, Kibret Mazengia, et al.
Journal of Neuroimmunology
|
November 25, 2021
Expression of cerebellar degeneration-related proteins CDR2 and CDR2L in human and rat brain tissue
Margrethe Raspotnig, Torbjørn Kråkenes, Ida Herdlevær, et al.
Oncotarget
|
May 31, 2018
Expression of the onconeural protein CDR1 in cerebellum and ovarian cancer
Cecilie Totland, Torbjørn Kråkenes, Kibret Mazengia, et al.
Annals of Neurology
|
May 24, 2020
Reply to "CDR2 and CDR2L Yo Antigens in Paraneoplastic Cerebellar Degeneration"
Torbjørn Kråkenes, Ida Herdlevaer, Margrethe Raspotnig, et al.
Cancer Immunology, Immunotherapy : CII
|
August 15, 2009
Antibody to CCDC104 is associated with a paraneoplastic antibody to CDR2 (anti-Yo)
Cecilie Totland, Geir Bredholt, Mette Haugen, et al.
Acta Neuropathologica
|
October 25, 2014
Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis
Manja Schubert, Debabrata Panja, Mette Haugen, et al.
European Journal of Neurology
|
March 13, 2023
A cerebellar degeneration-related protein 2-like cell-based assay for anti-Yo detection in patients with paraneoplastic cerebellar degeneration
Kjell Inge Erikstad, Ida Herdlevaer, Elise Peter, et al.
Page
of 2